Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS
Transcenta Holding Limited announced late-breaking presentation of preclinical study results of novel humanized LIV-1 antibody based ADCs at 2024 San Antonio Breast Cancer Symposium (SABCS).
December 13, 2024
by PRNewswire
Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002
Transcenta Holding Limited ("Transcenta"), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics...
September 28, 2021
by prnasia
Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction
Transcenta Holding Limited, a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has ...
July 29, 2021
by prnasia
Transcenta Announces First Patient Dosed in Global Phase I Clinical Trial of PD-L1/TGF-β Bi-functional Antibody TST005
Transcenta Holding Limited announces that the first US patient has been dosed in the global Phase I clinical trial of PD-L1/TGF-β bi-functional antibody TST005.
July 15, 2021
by prnasia
Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002
Transcenta Holding Limited announces that NMPA has accepted IND application of its anti-sclerostin monoclonal antibody TST002.
July 7, 2021
by prnasia
Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
Transcenta Holding Limited announces that promising anti-tumor responses have been observed in the ongoing TST001 (anti-Claudin18.2 monoclonal antibody) trials.
July 5, 2021
by prnasia
Transcenta Announced Completion of First Patient Dosing in PET-CT Imaging Study of Radionuclide-Labeled CLDN18.2 Antibody
Transcenta Holding Limited announced completion of first patient dosing in PET-CT imaging study of radionuclide-labeled CLDN18.2 antibody.
June 2, 2021
by prnasia
Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies
Transcenta Holding Limited, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the ...
May 20, 2021
by prnasia
Transcenta Announces Updated Clinical Data from Phase I Study of pH-Dependent PD-L1 Antibody MSB2311 to Be Presented at the 2021 ASCO Annual Meeting
Transcenta Holding Limited, a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that the updated phase I clinical data on the ...
May 14, 2021
by prnasia
Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005
Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of ...
April 21, 2021
by prnasia
Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Ga
Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been ...
April 19, 2021
by prnasia
Transcenta Announces Appointments of Dr. Xichen Zhang as Senior Vice President of Manufacturing and Dr. Steven Yu as Senior Vice President of DMPK and Translational Science
Transcenta today announced the expansion of its senior management team by appointing Dr. Xichen Zhang as Senior Vice President of Manufacturing and Dr. Steven Yu as Senior Vice President of DMPK & Translational Science.
March 24, 2021
by prnasia